TP53BP2抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Mouse kidney tissue, 293T cells, 231 cells, Primary antibody: P08053(TP53BP2 Antibody) at dilution 1/375, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08053(TP53BP2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain  tissue using P08053(TP53BP2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The TP53BP2 antibody is a crucial tool in cancer research, targeting the Tumor Protein p53 Binding Protein 2 (TP53BP2/ASPP2), a key regulator of apoptosis and DNA damage response. TP53BP2 interacts with p53. enhancing its pro-apoptotic activity by selectively promoting the transcription of apoptotic genes over cell-cycle arrest genes. This protein also engages with other tumor suppressors (e.g., ASPP1) and oncoproteins (e.g., Bcl-2), positioning it at the crossroads of cellular stress signaling pathways. Dysregulation of TP53BP2 is implicated in various cancers, with reduced expression linked to tumor progression and chemotherapy resistance.

Antibodies against TP53BP2 are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its expression patterns, subcellular localization, and interactions in normal versus cancerous tissues. These antibodies typically target specific domains, such as the N-terminal proline-rich region or the C-terminal SH3 domain, enabling precise detection of full-length proteins or isoforms. Validated antibodies undergo rigorous testing for specificity through knockout cell lines or siRNA knockdown experiments.

Research utilizing TP53BP2 antibodies has shed light on its dual roles—acting as a tumor suppressor in certain contexts while paradoxically promoting invasion in others—depending on cellular microenvironment and post-translational modifications. Such insights drive exploration of TP53BP2 as a prognostic biomarker or therapeutic target, particularly in cancers with p53 mutations or dysregulated apoptosis pathways.